---
layout: default
title: Etomidate
parent: 僅模型預測 (L5)
nav_order: 274
evidence_level: L5
indication_count: 0
---

# Etomidate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Etomidate: No TxGNN Repurposing Prediction Available

## One-Sentence Summary

Etomidate (DB00292) is an intravenous hypnotic agent most commonly used for anesthesia induction and procedural sedation. The current Evidence Pack contains no TxGNN model predictions for new therapeutic indications, and critical data — including mechanism of action, regulatory approvals, and safety profile — has not yet been retrieved. With no predicted indications and no supporting evidence to evaluate, this candidate cannot advance to repurposing assessment at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not populated in current Evidence Pack |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — No prediction generated; no supporting studies |
| Canada Market Status | Not marketed (0 approved products) |
| Number of DINs | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline produced no candidate repurposing indications for Etomidate in this run, and two blocking data gaps — mechanism of action and regulatory safety data — remain unresolved. There is no sufficient basis to conduct a repurposing evaluation.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction pipeline** for Etomidate (DB00292) and confirm whether the absence of predicted indications reflects a true model result or a pipeline failure
- **Retrieve MOA from DrugBank** (DB00292) — currently listed as a blocking data gap (DG002); this is essential for mechanistic plausibility analysis
- **Parse package insert PDF from Health Canada** — safety warnings and contraindications are currently unavailable (DG001, severity: Blocking), preventing S1 safety screening
- **Clarify Canada regulatory status** — confirm whether any Etomidate products are approved under a DIN, as the current data shows zero licenses; Etomidate is marketed in several jurisdictions under brand names such as Amidate and requires verification against the Health Canada drug product database
- **Resubmit Evidence Pack** once the above data sources have been ingested, to generate a complete v5 evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

